BRPI0815576A2 - Método para produzir uma linha celular que produz uma proteína terapêutica, segunda linha celular transformada com uma segunda seqüência de polinucleotídeos, vetor, cassete de expressão amplificado, linha celular ou sua progênie, e, anticorpo. - Google Patents
Método para produzir uma linha celular que produz uma proteína terapêutica, segunda linha celular transformada com uma segunda seqüência de polinucleotídeos, vetor, cassete de expressão amplificado, linha celular ou sua progênie, e, anticorpo.Info
- Publication number
- BRPI0815576A2 BRPI0815576A2 BRPI0815576A BRPI0815576A2 BR PI0815576 A2 BRPI0815576 A2 BR PI0815576A2 BR PI0815576 A BRPI0815576 A BR PI0815576A BR PI0815576 A2 BRPI0815576 A2 BR PI0815576A2
- Authority
- BR
- Brazil
- Prior art keywords
- cell line
- progene
- vector
- producing
- polynucleotide sequence
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/02—Recovery or purification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/60—Vectors containing traps for, e.g. exons, promoters
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/40—Vector systems having a special element relevant for transcription being an insulator
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US95677207P | 2007-08-20 | 2007-08-20 | |
PCT/EP2008/060834 WO2009024567A1 (en) | 2007-08-20 | 2008-08-19 | Production method |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0815576A2 true BRPI0815576A2 (pt) | 2015-02-18 |
Family
ID=40070558
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0815576 BRPI0815576A2 (pt) | 2007-08-20 | 2008-08-19 | Método para produzir uma linha celular que produz uma proteína terapêutica, segunda linha celular transformada com uma segunda seqüência de polinucleotídeos, vetor, cassete de expressão amplificado, linha celular ou sua progênie, e, anticorpo. |
Country Status (13)
Country | Link |
---|---|
US (2) | US9163249B2 (pt) |
EP (3) | EP2527367A1 (pt) |
JP (2) | JP5592258B2 (pt) |
KR (1) | KR101637533B1 (pt) |
CN (1) | CN101848936B (pt) |
AU (1) | AU2008290607B2 (pt) |
BR (1) | BRPI0815576A2 (pt) |
CA (1) | CA2695484C (pt) |
DK (1) | DK3216802T3 (pt) |
EA (1) | EA022990B1 (pt) |
ES (2) | ES2840725T3 (pt) |
MX (1) | MX2010002003A (pt) |
WO (1) | WO2009024567A1 (pt) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2527367A1 (en) * | 2007-08-20 | 2012-11-28 | Glaxo Group Limited | Production method |
AU2010223354A1 (en) * | 2009-03-10 | 2011-09-08 | Dsm Ip Assets B.V. | Method for improving the yield of a polypeptide |
EP2516664B1 (en) * | 2009-12-21 | 2015-07-22 | Pharmathene Inc. | Recombinant butyrylcholinesterases and truncates thereof |
WO2012001073A2 (en) | 2010-07-01 | 2012-01-05 | Glaxo Group Limited | Improved method for selecting high producing cell lines |
GB201112429D0 (en) | 2011-07-19 | 2011-08-31 | Glaxo Group Ltd | Antigen-binding proteins with increased FcRn binding |
EP2948473A1 (en) | 2013-01-24 | 2015-12-02 | GlaxoSmithKline Intellectual Property Development Limited | Tnf-alpha antigen-binding proteins |
MX2018005084A (es) * | 2015-11-05 | 2019-05-16 | Bamboo Therapeutics Inc | Genes de ataxia de friedreich modificados y vectores para terapia genica. |
WO2017162265A1 (en) | 2016-03-21 | 2017-09-28 | Biontech Rna Pharmaceuticals Gmbh | Trans-replicating rna |
WO2017162266A1 (en) | 2016-03-21 | 2017-09-28 | Biontech Rna Pharmaceuticals Gmbh | Rna replicon for versatile and efficient gene expression |
CA3075549A1 (en) | 2017-09-13 | 2019-03-21 | Biontech Rna Pharmaceuticals Gmbh | Rna replicon for reprogramming somatic cells |
AU2018333530A1 (en) | 2017-09-13 | 2020-02-27 | Biontech Cell & Gene Therapies Gmbh | RNA replicon for expressing a T cell receptor or an artificial T cell receptor |
WO2021245090A1 (en) | 2020-06-04 | 2021-12-09 | BioNTech SE | Rna replicon for versatile and efficient gene expression |
CA3234214A1 (en) | 2021-10-18 | 2023-04-27 | BioNTech SE | Methods for determining mutations for increasing modified replicable rna function and related compositions and their use |
AU2022369342A1 (en) | 2021-10-18 | 2024-03-14 | BioNTech SE | Modified replicable rna and related compositions and their use |
WO2023213378A1 (en) | 2022-05-02 | 2023-11-09 | BioNTech SE | Replicon compositions and methods of using same for the treatment of diseases |
WO2024017479A1 (en) | 2022-07-21 | 2024-01-25 | BioNTech SE | Multifunctional cells transiently expressing an immune receptor and one or more cytokines, their use and methods for their production |
WO2024056856A1 (en) | 2022-09-15 | 2024-03-21 | BioNTech SE | Systems and compositions comprising trans-amplifying rna vectors with mirna |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0953639A1 (en) * | 1998-04-30 | 1999-11-03 | Boehringer Ingelheim International GmbH | FAPalpha-specific antibody with improved producibility |
EP1373547A4 (en) * | 2001-03-27 | 2006-01-18 | Smithkline Beecham Corp | CONTROL OF GLYCOFORMS IN IGG |
PL377769A1 (pl) * | 2002-10-09 | 2006-02-20 | Rinat Neuroscience Corp. | Sposób leczenia choroby Alzheimera z zastosowaniem przeciwciał skierowanych przeciw peptydowi beta amyloidu i ich kompozycje |
WO2004046168A2 (en) * | 2002-11-15 | 2004-06-03 | The Henry M. Jackson Foundation | Recombinant hiv-1 subclass d envelope glycoproteins |
US7384744B2 (en) * | 2002-11-29 | 2008-06-10 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such products |
US7485297B2 (en) * | 2003-08-12 | 2009-02-03 | Dyax Corp. | Method of inhibition of vascular development using an antibody |
US20070287163A1 (en) * | 2004-05-17 | 2007-12-13 | Crucell Holland B.V. | Methods for Diagnosis of Acute Myeloid Leukemia |
US7462697B2 (en) * | 2004-11-08 | 2008-12-09 | Epitomics, Inc. | Methods for antibody engineering |
AR052051A1 (es) * | 2004-12-15 | 2007-02-28 | Neuralab Ltd | Anticuerpos ab humanizados usados en mejorar la cognicion |
CA2589860A1 (en) * | 2005-01-24 | 2006-08-03 | Amgen Inc. | Humanized anti-amyloid antibody |
AU2006249087B2 (en) * | 2005-05-20 | 2012-05-17 | Lonza Biologics Plc | High-level expression of recombinant antibody in a mammalian host cell |
AR057233A1 (es) * | 2005-12-12 | 2007-11-21 | Hoffmann La Roche | Glicosilacion en la region variable |
KR101263294B1 (ko) * | 2006-03-30 | 2013-06-04 | 글락소 그룹 리미티드 | 아밀로이드베타 펩티드에 대한 항체 |
MX2008012485A (es) * | 2006-03-30 | 2008-10-10 | Novartis Ag | Composiciones y metodos de uso para anticuerpos de c-met. |
EP2527367A1 (en) * | 2007-08-20 | 2012-11-28 | Glaxo Group Limited | Production method |
-
2008
- 2008-08-19 EP EP20120171016 patent/EP2527367A1/en not_active Withdrawn
- 2008-08-19 JP JP2010521409A patent/JP5592258B2/ja active Active
- 2008-08-19 ES ES17159323T patent/ES2840725T3/es active Active
- 2008-08-19 EP EP20080787316 patent/EP2185591B1/en active Active
- 2008-08-19 CA CA2695484A patent/CA2695484C/en not_active Expired - Fee Related
- 2008-08-19 BR BRPI0815576 patent/BRPI0815576A2/pt not_active Application Discontinuation
- 2008-08-19 MX MX2010002003A patent/MX2010002003A/es not_active Application Discontinuation
- 2008-08-19 EP EP17159323.9A patent/EP3216802B1/en active Active
- 2008-08-19 US US12/674,069 patent/US9163249B2/en active Active
- 2008-08-19 EA EA201000205A patent/EA022990B1/ru not_active IP Right Cessation
- 2008-08-19 WO PCT/EP2008/060834 patent/WO2009024567A1/en active Application Filing
- 2008-08-19 KR KR1020107006104A patent/KR101637533B1/ko active IP Right Grant
- 2008-08-19 CN CN200880111547.1A patent/CN101848936B/zh active Active
- 2008-08-19 ES ES08787316.2T patent/ES2473623T3/es active Active
- 2008-08-19 AU AU2008290607A patent/AU2008290607B2/en not_active Ceased
- 2008-08-19 DK DK17159323.9T patent/DK3216802T3/da active
-
2014
- 2014-07-31 JP JP2014155890A patent/JP6029625B2/ja active Active
-
2015
- 2015-09-30 US US14/870,065 patent/US10633673B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP2185591A1 (en) | 2010-05-19 |
AU2008290607B2 (en) | 2013-11-14 |
KR101637533B1 (ko) | 2016-07-11 |
KR20100065332A (ko) | 2010-06-16 |
DK3216802T3 (da) | 2021-01-04 |
JP5592258B2 (ja) | 2014-09-17 |
CA2695484A1 (en) | 2009-02-26 |
EP2185591B1 (en) | 2014-05-14 |
US9163249B2 (en) | 2015-10-20 |
EP3216802A1 (en) | 2017-09-13 |
EP3216802B1 (en) | 2020-10-07 |
CA2695484C (en) | 2018-05-01 |
MX2010002003A (es) | 2010-03-10 |
US20160010111A1 (en) | 2016-01-14 |
ES2473623T3 (es) | 2014-07-07 |
EA201000205A1 (ru) | 2011-02-28 |
EP2527367A1 (en) | 2012-11-28 |
JP6029625B2 (ja) | 2016-11-24 |
WO2009024567A1 (en) | 2009-02-26 |
US10633673B2 (en) | 2020-04-28 |
CN101848936B (zh) | 2017-05-03 |
US20110040074A1 (en) | 2011-02-17 |
EA022990B1 (ru) | 2016-04-29 |
ES2840725T3 (es) | 2021-07-07 |
JP2010536358A (ja) | 2010-12-02 |
CN101848936A (zh) | 2010-09-29 |
AU2008290607A1 (en) | 2009-02-26 |
JP2015027298A (ja) | 2015-02-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0815576A2 (pt) | Método para produzir uma linha celular que produz uma proteína terapêutica, segunda linha celular transformada com uma segunda seqüência de polinucleotídeos, vetor, cassete de expressão amplificado, linha celular ou sua progênie, e, anticorpo. | |
BRPI0813242A2 (pt) | Proteína de ligação a antígeno isolada, ácido nucléico isolado, vetor, célula hospedeira isolada, método para a produção de uma proteína de ligação a antígeno, e, composição. | |
ITVE20060045A1 (it) | Dispositivo riscaldatore per calzature, guanti e simili. | |
BRPI0811610A2 (pt) | Aço com baixa densidade, apresentando uma boa aptidão ao encaixe | |
BRPI0813216A2 (pt) | Inibidores de proteínas cinases e métodos para usá-los. | |
BRPI0810194A2 (pt) | Método para gestão de mobilidade em uma arquitetura de sistema de apoio à mobilidade entre diferentes sistemas de acesso. | |
BRPI0716439A2 (pt) | formulaÇÕes de flibanserina e mÉtodo para fabricaÇço das mesmas. | |
BRPI0813914A2 (pt) | Sistema, e, método. | |
BRPI0819714A2 (pt) | Formulações de proteína e métodos de produção das mesmas. | |
WO2005099775A3 (en) | Labeled anwexin for predicting the response to a therapeutic regimen | |
WO2007084402A8 (en) | Computer based system for training workers | |
BRPI0714170A2 (pt) | Processos para a fabricação de 1,2-dicloroetano, de cloreto de vinila, e de cloreto de polivinila. | |
BRPI0716068A2 (pt) | Bactéria recombinante, e, métodos para produzir bactéria recombinante e etanol a partir de uma fonte de oligossacarídeo, kit, e, e. coli | |
FR2905564B1 (fr) | Fourrages. | |
BRPI0811492B8 (pt) | método para produzir uma bebida láctea acidificada, bebida láctea acidificada, e, polipeptídeo isolado com atividade desamidase | |
FR2932486B1 (fr) | Procede de preparation d'un polyamideimide, polyamideimide et composition comprenant ce polyamideimide. | |
BRPI1013484A2 (pt) | "protease, dna, vetor de expressão , célula transformada, e, método para produzir uma protease". | |
GB2447924C (en) | An animal access system. | |
BRPI0814977A2 (pt) | Sistema, e, método. | |
DK1987651T3 (da) | Fremgangsmåde til at optimere datastrømmen mellem en router og en multimedienhed | |
BRPI0812871A2 (pt) | " recipiente, e, método para formar o mesmo ". | |
BRPI0815690A2 (pt) | Métodos para produzir ácido succínico, e para produzir um polímero contendo ácido succínico. | |
HK1110386A1 (en) | Quantitative assaying method for 3, 5-substituted oxazolidinones | |
DE112005001016A5 (de) | Bakterielles System zum Proteintransport in eukaryontische Zellen | |
ITTO20060846A1 (it) | Dispositivo di connessione rapida, particolarmente per tubi e simili. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL |